Special Issue "Safety and Autoimmune Response to SARS-CoV-2 Vaccination"
Deadline for manuscript submissions: closed (20 November 2023) | Viewed by 27931
Interests: PET/CT; COVID-19; vaccine; vaccination
Special Issues, Collections and Topics in MDPI journals
Coronavirus disease 2019 (COVID-19) is a new global public health crisis affecting the entire world. The main treatment options for COVID-19 are antiviral (to prevent viral replication) and immunomodulatory/anti-inflammatory drugs (to avoid tissue damage). Most of the treatments are for symptomatic relief, but none of them are ideal. Thus, prevention (vaccination) is incredibly important. In addition to vaccine efficacy, data about safety are crucial for health authorities to approve vaccine use.
Following the introduction and wide use of SARS-CoV-2 vaccination, different adverse effects and complications were reported. Although important post-marketing surveillance of vaccines is ongoing, SARS-CoV-2 vaccines are currently still considered highly effective and safe, even with neurological adverse events following immunization (AEFI). These transient symptoms include cerebral venous sinus thrombosis, demyelinating episodes, lymphadenopathy, nausea, cognitive decline, or local influences of swelling, erythema, pain, fever/chills, fatigue, headache, dizziness, muscle weakness, and myalgia/arthralgia.
We are pleased to invite you to contribute with your work to this Special Issue on “Safety and Autoimmune Response to SARS-CoV-2 Vaccination”.
This Special Issue aims to publish high-quality reviews, regular research papers, communications, and case reports on the safety of the SARS-CoV-2 vaccine in the general population and in special groups, proposals of different schedules and their effects on vaccine safety, security of neurological adverse events following immunization, and other aspects that may be proposed.
We look forward to receiving your contributions.
Dr. Ming-Hui Yang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- COVID-19 vaccine
- adverse events following immunization